BABA vs GEF-B

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

GEF-B presents a conflicting profile characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock has shown strong 1-year price momentum (+50.2%), this is decoupled from a concerning decline in revenue (-29.8% Q/Q) and a dangerously high dividend payout ratio of 88.98%. The current price of $83.34 sits between the defensive Graham Number ($65.38) and the growth-based Intrinsic Value ($107.08), suggesting a valuation that is currently pricing in growth that the revenue data does not support.